Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Short-term Investments (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Short-term Investments for 3 consecutive years, with $57.5 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Short-term Investments fell 52.18% year-over-year to $57.5 million, compared with a TTM value of $57.5 million through Sep 2024, down 52.18%, and an annual FY2023 reading of $57.7 million, up 1441.89% over the prior year.
  • Short-term Investments was $57.5 million for Q3 2024 at Oramed Pharmaceuticals, up from $1.8 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $120.2 million in Q3 2023 and bottomed at $334000.0 in Q2 2023.
  • Average Short-term Investments over 3 years is $31.0 million, with a median of $6.6 million recorded in 2022.
  • The sharpest move saw Short-term Investments tumbled 94.97% in 2023, then skyrocketed 21835.79% in 2024.
  • Year by year, Short-term Investments stood at $3.7 million in 2022, then skyrocketed by 1441.89% to $57.7 million in 2023, then fell by 0.45% to $57.5 million in 2024.
  • Business Quant data shows Short-term Investments for ORMP at $57.5 million in Q3 2024, $1.8 million in Q2 2024, and $80.3 million in Q1 2024.